FDA Approves Hympavzi for Hemophilia
TUESDAY, Oct. 15, 2024 (HealthDay News) -- The U.S. Food and Drug Administration (FDA) approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and …